Multiple Partnering Rooms Already Reserved Ahead of BIOCHINA 2026

Several Partnering rooms at BIOCHINA 2026 have already been reserved, with headquarter-level teams from leading multinational corporations confirmed to attend, including Bayer, Eli Lilly, Pfizer, Novartis, Novo Nordisk, and Bristol Myers Squibb. This early demand reflects the high level of interest from global and Chinese biopharma leaders in exploring strategic partnerships, licensing opportunities, and collaborative innovation.

BIOCHINA 2026, taking place in Suzhou from March 12 to 14, offers a unique platform for engagement with thousands of Chinese biotech decision-makers, including senior executives in business development, licensing, strategy, and management. Attendees will have the opportunity to meet with potential partners face-to-face, discuss pipeline projects, explore investment opportunities, and forge collaborations that span local and international markets.

The event features a fully upgraded Partnering System, designed to provide a faster, more intuitive experience for scheduling and managing meetings. With this system, participants can maximize their networking efficiency, ensuring every interaction is meaningful and strategically aligned. Whether you are seeking co-development opportunities, licensing deals, or insight into emerging trends in the Chinese biopharma landscape, BIOCHINA’s Partnering platform offers a comprehensive solution.

Industry experts note that the Chinese biopharma sector continues to grow rapidly, with increasing international collaboration and investment driving innovation across drugs, biologics, gene and cell therapies. By participating in BIOCHINA 2026 Partnering, global companies gain direct access to this vibrant ecosystem and can connect with local partners who are actively shaping the future of medicine.

Early-bird registration pricing is available until December 31. Companies and executives are encouraged to secure their Partnering rooms as soon as possible, as multiple rooms have already been reserved and availability is limited. Don’t miss the chance to engage with top-tier decision-makers from leading biopharma companies worldwide.

Register here: BIOCHINA Partnering Early-Bird